变更经营范围、注册资本及修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 河南羚锐制药股份有限公司（以下简称"公司"）于 2024 年 11 月 29 日召开 第九届董事会第十二次会议，审议通过《关于变更经营范围、注册资本及修订< 公司章程>的议案》。具体情况如下： 一、公司经营范围变更情况 根据公司实际经营需要，拟对原经营范围进行变更。具体情况如下： 变更前经营范围：药品、保健用品、保健食品、消毒用品、医疗器械的生产、 销售（凭证）；糖果、调味品、营养食品、食品添加剂的制造、销售；饮料制造、 销售；体育用品制造、销售；日用化学产品(不含易燃、易爆危险品)制造、销售； 日用杂品制造、销售；新产品、新技术的研究、开发与技术服务；自营本企业自 产产品及相关技术的出口业务；自营本企业生产、科研所需的原辅材料、机械设 备、仪器仪表、零配件及相关技术的进口业务；进料加工，"三来一补"；信息咨 询服务；食品互联网销售，第二类增值电信业务；药品互联网信息服务，医疗器 械互联网信息服务，互联网信息服务；对房地产、技 ...

河南羚锐制药股份有限公司 2024年员工持股计划 证券简称：羚锐制药 证券代码：600285 本公司及董事会全体成员保证本次员工持股计划不存在虚假记载、误导性陈 述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 （草案） 二〇二四年十一月 声明 二、若员工认购金额较低时，本次员工持股计划存在无法成立的风险；若 员工认购资金不足，本次员工持股计划存在低于预计规模的风险。 三、本次员工持股计划设立后将由公司自行管理，本次员工持股计划涉及 的具体资金来源、出资金额、实施方案等为初步结果，能否完成实施，存在不 确定性； 四、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 1 风险提示 一、本次员工持股计划需经公司股东大会批准后方可实施，本次员工持股计 划能否获得公司股东大会批准，存在不确定性。 2 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 一、本次员工持股计划系依据《中华人民共和国公司法》《中华人民共和国证 券法》《关于上市公司实施员工持股计划试点的指导意见》《上海证券交易所上 市公司自律监管指引第1号—规范运作》及其他有关法律、法规、规范性文件以及 ...

证券简称：羚锐制药 证券代码：600285 河南羚锐制药股份有限公司 2024年员工持股计划 （草案）摘要 二〇二四年十一月 声明 本公司及董事会全体成员保证本次员工持股计划不存在虚假记载、误导性陈述 或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 1 风险提示 一、本次员工持股计划需经公司股东大会批准后方可实施，本次员工持股计划 能否获得公司股东大会批准，存在不确定性。 二、若员工认购金额较低时，本次员工持股计划存在无法成立的风险；若员工 认购资金不足，本次员工持股计划存在低于预计规模的风险。 三、本次员工持股计划设立后将由公司自行管理，本次员工持股计划涉及的具 体资金来源、出资金额、实施方案等为初步结果，能否完成实施，存在不确定性； 本次员工持股计划实施后，公司全部有效的员工持股计划所持有的股票总数 累计不超过公司股本总额的10%，任一持有人持有的员工持股计划份额所对应的 标的股票数量不超过公司股本总额的1%。员工持股计划持有的股票总数不包括员 工在公司首次公开发行股票上市前获得的股份、通过二级市场自行购买的股份及 通过股权激励获得的股份。 四、公司后续将根据规定披露相关进展情况，敬请 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase of over 15% compared to the CSI 300 index within the next six months [11]. Core Views - The company, Henan Lingrui Pharmaceutical Co., Ltd., has shown a solid performance in the first three quarters of 2024, with a revenue of 2.759 billion yuan, representing a year-on-year growth of 10.07%, and a net profit of 574 million yuan, up 23.10% year-on-year [3][4]. - The company's main revenue and gross profit source is its orthopedic external plaster products, with a gross margin of 75%, which has improved by 0.37 percentage points compared to the same period last year [3][4]. - The report projects earnings per share (EPS) for 2024, 2025, and 2026 to be 1.28 yuan, 1.51 yuan, and 1.75 yuan respectively, with corresponding dynamic price-to-earnings ratios of 16.88, 14.29, and 12.34 [4][6]. Summary by Sections Company Overview - Henan Lingrui Pharmaceutical Co., Ltd. was established in 1988 and has undergone several transformations, including a joint venture in 1992 and a public listing in 2000 [2]. - The largest shareholder is Henan Lingrui Group, holding a 21.48% stake as of the third quarter of 2024 [2]. Financial Performance - For the first three quarters of 2024, the company achieved a net profit of 574 million yuan, with a basic EPS of 1.02 yuan [3]. - The third quarter alone saw a revenue of 853 million yuan, a 5.83% increase year-on-year, and a net profit of 161 million yuan, up 7.8% year-on-year [3]. Profitability Metrics - The gross margin stands at 75%, and the net margin is 20.80%, both showing improvements from the previous year [3]. - The report highlights a decrease in sales and management expense ratios, indicating better cost management [3]. Future Projections - Revenue is expected to grow from 3.808 billion yuan in 2024 to 5.036 billion yuan in 2026, with annual growth rates of approximately 15% [6][9]. - Net profit is projected to increase from 724 million yuan in 2024 to 990 million yuan in 2026, reflecting a robust growth trajectory [6][9].

Investment Rating - The report maintains an "Accumulate" rating for the company [1][5][14] Core Views - The company has shown a slowdown in revenue and profit growth in Q3, attributed to industry disturbances affecting specific products [2][3] - Despite the short-term challenges, the long-term outlook remains positive due to the company's strong brand value and product line, particularly in the orthopedic medication market driven by an aging population [3][5] Financial Performance Summary - For the first three quarters of 2024, the company achieved revenue of 2.759 billion yuan, a year-on-year increase of 10.07%, and a net profit attributable to shareholders of 574 million yuan, up 23.10% year-on-year [2][3] - Q3 2024 revenue was 853 million yuan, reflecting a year-on-year growth of 5.83%, while net profit for the same period was 161 million yuan, up 7.80% year-on-year [2][3] - The gross margin for Q3 was 72.68%, with a net profit margin of 18.85%, both showing a decline compared to the previous quarter [2] Financial Metrics - The company is projected to achieve revenues of 3.672 billion yuan, 4.153 billion yuan, and 4.660 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 10.9%, 13.1%, and 12.2% [1][5] - Net profit forecasts for the same years are 693 million yuan, 837 million yuan, and 990 million yuan, with growth rates of 22%, 21%, and 18% respectively [1][5] - The report indicates a continuous improvement in financial metrics, with a return on equity (ROE) projected to reach 22.8% in 2024 and 24.1% in 2025 [1][3][8]

证券代码：600285 证券简称：羚锐制药 公告编号：2024-043 号 河南羚锐制药股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 18 日(星期一) 至 11 月 22 日(星期五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 600285@lingrui.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 本次投资者说明会以网络互动形式召开，公司将针对 2024 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2024 年 11 月 25 日(星期一) 下午 16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： （一） 会 ...

证券代码：600285 证券简称：羚锐制药 公告编号：2024-042 号 莫匹罗星软膏由葛兰素史克公司研制，最早于 1988 年在英国获得批准上市， 于 1993 年在我国上市销售，商品名为"百多邦"。莫匹罗星软膏为局部外用抗生 素，适用于革兰阳性球菌引起的皮肤感染，例如：脓疱病、疖肿、毛囊炎等原发 性皮肤感染以及湿疹合并感染、溃疡合并感染、创伤合并感染等继发性皮肤感染。 莫匹罗星软膏为《国家医保目录》乙类产品、《国家基本药物目录》产品。 河南羚锐制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的莫匹罗星软膏《药品注册证书》， 现将相关情况公告如下： 一、药品的基本情况 药品名称：莫匹罗星软膏 剂型：软膏剂 规格：2%（15g：0.3g） 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 上市许可持有人：河南羚锐制药股份有限公司 生产企业：河南羚锐生物药业有限公司 药品批准文号：国药准字 H20249203 药品批准文号有效期：至 2029 年 10 月 28 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的 ...

Investment Rating - The investment rating for the company is "Buy" with a maintained rating [4]. Core Views - The company has shown steady revenue growth, benefiting from the aging population trend, with a reported revenue of 2.75 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 10.1% [1]. - The company is undergoing a second phase of marketing reform, which is expected to enhance its performance elasticity [4]. - The company is a well-known brand in the traditional Chinese medicine patch market, with a diverse product portfolio that supports long-term development [3]. Financial Performance Summary - For Q1-Q3 2024, the company achieved a net profit of 570 million yuan, up 23.1% year-on-year, and a non-recurring net profit of 540 million yuan, up 22.5% year-on-year [1]. - In Q3 2024, the company reported revenue of 850 million yuan, a 5.8% increase year-on-year, with a net profit of 160 million yuan, reflecting a 7.8% year-on-year growth [1]. - The gross profit margin for Q1-Q3 2024 was 75%, an increase of 0.4 percentage points year-on-year, while the sales expense ratio decreased by 1.4 percentage points to 44.4% [2]. Product and Market Positioning - The company has a strong position in the traditional Chinese medicine patch market, with its unique product Tongluo Qutong Gao ranking third in sales among traditional Chinese medicine patches in public hospitals as of H1 2022 [3]. - The company is expanding its product types, including tablets, capsules, and ointments, which enhances its development path and creates synergies with its patch products [3]. - The company is increasing its R&D investment to accelerate the development of new products, focusing on areas such as orthopedic, cardiovascular, and brain health [3]. Earnings Forecast and Valuation - The forecasted net profits for the company are expected to reach 680 million yuan, 800 million yuan, and 930 million yuan for the years 2024, 2025, and 2026, respectively, maintaining previous estimates [4]. - The corresponding price-to-earnings (P/E) ratios are projected to be 18, 15.2, and 13 times for the same years [4].

Summary of Conference Call Company and Industry - The conference call pertains to a pharmaceutical company focusing on various drug products, including oral medications and topical treatments, within the healthcare industry. Key Points and Arguments Market Performance and Sales Strategy - The company has faced challenges in customer traffic and pricing in pharmacies, impacting the promotion of its premium product series. It plans to enhance sales strategies for these products in response to the aging population and the increasing prevalence of joint diseases among younger demographics [1][2] - The sales of fentanyl have shown a growth rate of over 15% in the first three quarters of the year, with expectations for an annual growth of around 20% due to enhanced academic promotion and management of distributors [1][2] - The oral medication segment, particularly the "Peiyuan Tongnao Capsule," has seen a revenue growth of approximately 5% in the first three quarters, with a stronger performance expected in the third quarter due to seasonal increases in cardiovascular diseases [2][3] Product Performance - Other products, including various traditional Chinese medicine formulations, have generated over 100 million yuan in revenue with a growth rate of about 10% year-on-year [3] - The company is focusing on optimizing production efficiency through automation and cost control measures, which include strategic procurement and flexible production planning [4][5] Brand Development and Marketing - The company is committed to building a more influential health brand, with significant investments in brand marketing and community health initiatives across over 300 cities [4][5] - Marketing strategies include leveraging social media to enhance brand awareness and consumer engagement, alongside traditional advertising methods [5] Financial Outlook - The company aims for a revenue growth of 10% to 15% and a net profit growth of over 15% in the coming years, with specific guidance for 2025 to be provided later [5][6] - The company has reported a strong inventory turnover rate of 1.55, attributed to strategic procurement practices [6][7] Challenges and Risks - The company acknowledges external challenges affecting OTC sales growth, with expectations for a gradual recovery in the fourth quarter [11][12] - There are concerns regarding the impact of pricing regulations in certain cities, which may affect sales dynamics [31][32] Future Growth Potential - The company anticipates stable growth for its flagship products, with the "Two Tigers" brand expected to maintain a steady increase in sales, albeit at a slower pace than the growth of the population aged 45 and above [10][12] - The company is exploring new product lines and market opportunities, particularly in the realm of traditional Chinese medicine and OTC products [21][22] Additional Important Information - The company is actively managing its cash flow, with fluctuations noted in the third quarter due to increased accounts receivable and strategic business decisions [26][27] - The company is cautious about future cost increases due to raw material price volatility but remains optimistic about maintaining stable procurement practices [25][30] This summary encapsulates the key insights from the conference call, highlighting the company's strategic focus, market performance, and future outlook within the pharmaceutical industry.

Financial Performance - Revenue increased by 15% year-over-year, driven by strong sales in the Asia-Pacific region [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8%, primarily due to increased marketing and R&D investments [3]. Market Expansion - The company successfully entered two new markets in Europe, contributing to a 20% increase in international sales [4]. - A new distribution center was opened in South America to support regional growth [5]. - Strategic partnerships were formed with local retailers to enhance market penetration [6]. Product Development - Launched three new products in the tech segment, which accounted for 25% of total revenue [7]. - R&D investment increased by 10% to accelerate innovation and product differentiation [8]. - Customer feedback on the new product line has been overwhelmingly positive, with a 90% satisfaction rate [9]. Operational Efficiency - Implemented a new ERP system, reducing operational costs by 5% [10]. - Streamlined supply chain processes, resulting in a 15% reduction in delivery times [11]. - Employee training programs were enhanced, leading to a 20% improvement in productivity [12]. Sustainability Initiatives - Achieved a 30% reduction in carbon emissions through the adoption of renewable energy sources [13]. - Launched a recycling program that has successfully diverted 50% of waste from landfills [14]. - Committed to achieving net-zero emissions by 2030, with interim targets set for 2025 [15]. Corporate Governance - Appointed two new independent directors to the board, enhancing governance and oversight [16]. - Implemented a new whistleblower policy to ensure ethical practices and compliance [17]. - Conducted annual audits with no material findings, reinforcing financial integrity [18].